Hikma Pharmaceuticals tumbles after injectables margin outlook cut

Hikma Pharmaceuticals' shares fell as much as 10% after the company lowered its full-year core operating margin outlook for its injectables unit to 32-33% from a previous mid-30s percentage, citing the impact of a strong euro. This revised outlook for a key segment overshadowed the generic drugmaker's reported overall interim profit beat and maintained annual group guidance.

Analysis

Hikma Pharmaceuticals (HIK.L) experienced a significant share price decline of up to 10% following a downward revision to its full-year core operating margin guidance for the injectables business. The company now forecasts a margin between 32% and 33%, a reduction from the previous mid-30s percentage range, attributing the cut to the adverse impact of a strong euro. This specific guidance downgrade for a key segment has evidently overshadowed the company's otherwise positive performance, which included beating overall interim profit expectations and maintaining its annual guidance for the group. The market's strongly negative reaction suggests investor concern is focused on the profitability pressures and foreign exchange headwinds facing the injectables unit, rather than the stability of the consolidated group outlook.

Key Decisions for Investors

• Investors should closely monitor the impact of euro strength on the injectables unit's profitability, as this is the primary driver behind the current stock underperformance.
• Consider whether the 10% share price drop represents an overreaction, given that the company beat interim profit expectations and maintained its overall annual group outlook.
• Evaluate the company's ability to mitigate currency headwinds in the injectables segment, as any successful strategy could serve as a positive catalyst for the stock.